🇺🇸 FDA
Pipeline program

Laquinimod

LAQ-MS-305

Phase 3 small_molecule completed

Quick answer

Laquinimod for Multiple Sclerosis is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 3 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Multiple Sclerosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials